关键词: 拜耳 Steigerwald
2013年5月17日讯 /生物谷BIOON/ --拜耳(Bayer)日前宣布,已与德国中草药制造商Steigerwald Arzneimittelwerk GmbH签署了一项协议,收购该公司100%股份。Steigerwald位于德国达姆施塔特,是一家私人控股的制药公司,专门研究、开发、生产高质量中草药,其产品包括Iberogast和Laif,前者为功能性胃肠病药物,后者为中度至重度抑郁症治疗药物。
此次收购的相关财务细节尚未披露。在完成反垄断审查后,该笔交易预计将于2013年7月初完成。
“此次收购是加强保健消费品业务的战略举措,将扩大我们在胃肠功能紊乱治疗领域的产品组合,使我们有体会提升在德国、快速增长的东欧及中欧地区、独联体国家的存在感,”拜耳首席执行官Marijn Dekkers博士说道。
Steigerwald股东之一Klaus Moller称:“作为一个家族企业,我们为自身在培育和开发我们品牌方面所取得的成绩感到骄傲。我们相信,拜耳通过其广泛的市场推广、销售、分销及研究专长,能够将我们所取得成功提升到一个新的高度。”
Steigerwald在2012年的销售收入为6130万欧元,目前该公司员工总数约180人,拜耳将接管Steigerwald的员工,其总部、生产基地及销售机构将保留现有的结构。(Darmstadt)(生物谷Bioon.com)
英文原文:Bayer to acquire Steigerwald Arzneimittelwerk GmbH
Transaction includes Iberogast? and Laif? brands
Leverkusen, Germany, May 16, 2013 – Bayer signed an agreement Thursday to acquire 100% of the shares of Steigerwald Arzneimittelwerk GmbH, Darmstadt, Germany, a privately held pharmaceutical company specializing in pharmacy-only herbal medicines. Steigerwald’s product portfolio includes Iberogast? for the treatment of functional gastrointestinal disorders and Laif? for the treatment of mild to moderate depression. Financial details have not been disclosed. The transaction is subject to fulfillment of the usual conditions, including antitrust clearance, and is expected to close at the beginning of July 2013.
“This transaction is further evidence of our commitment to augment organic growth with strategic bolt-on acquisitions. It will allow us to provide consumers with an even broader range of self-care options,” said Dr. Marijn Dekkers, CEO of Bayer AG. “This acquisition broadens our product offering for the treatment of gastrointestinal disorders and gives us the opportunity to enhance our presence in Germany, the fast-growing regions of East-Central Europe, and the CIS countries.”
Klaus M?ller, one of Steigerwald’s shareholders, added: “As a family-owned business, we take great pride in what we have achieved in nurturing and developing our brands. We believe that Bayer, with its extensive marketing, sales, distribution and research expertise, is well positioned to take our success to the next level.”
Steigerwald generated sales of EUR 61.3 million in 2012. The company employs approximately 180 people and has its headquarters and manufacturing site in Darmstadt. Bayer has committed to take over all of Steigerwald’s employees. The Darmstadt site and the sales organization are to retain their existing structures.
(责任编辑:lili.zhao)